Consequences of Directive 2001/20/EC for investigator-initiated trials in the paediatric population—a field report
Authors:
- 27 February 2007
- journal article
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 166 (11) , 1169-1176
Abstract
On 4 April 2001, the European Parliament and Council enacted Directive 2001/20/EC, which had to be implemented in the national law of the European Union member states by May 2004. Its aim was to improve the quality of clinical trials and to assure the safety and well-being of trial subjects. We recently initiated the first paediatric investigator-initiated trial (IIT) at the University Hospital of Cologne according to Directive 2001/20/EC. This field report demonstrates the consequences and implications of the directive for paediatric IITs. Based on our experience, we agree that Directive 2001/20/EC improves the quality of clinical trials and assures the safety and well-being of trial subjects. However, at the same time, performing an IIT according to the new requirements is nearly impossible for clinicians and academic researchers without cooperating with expensive specialised experts, such as project managers, statisticians, data managers, pharmacists and monitors. Therefore, it is absolutely mandatory that financial support for paediatric IITs be adapted and increased in order to be able to meet the new requirements and obligations. Regulation (EC) No 141/2000 on orphan medicinal products and the recently adopted regulation on medicinal products for paediatric use (Paediatric Regulation) are important steps in improving clinical research in children. However, both regulations mainly encourage clinical research carried out by the pharmaceutical industry, whereas paediatric IITs are not in the scope of this legislation. We need to develop new concepts for funding to ensure future paediatric IITs, for example through specific grants from the European Union or member states.Keywords
This publication has 9 references indexed in Scilit:
- CRASH2 in Germany [ISRCTN86750102]Trials, 2006
- Report of the 1st meeting of the "Vienna Initiative to Save European Academic Research (VISAER)".2006
- Die Auswirkungen der 12. und der 14. Novelle zum AMG auf die Forschung mit Arzneimitteln für KinderZeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 2006
- A literature review on off-label drug use in childrenEuropean Journal of Pediatrics, 2005
- Ethical principles and operational guidelines for good clinical practice in paediatric research. Recommendations of the Ethics Working Group of the Confederation of European Specialists in Paediatrics (CESP)European Journal of Pediatrics, 2004
- Survey of unlicensed and off label drug use in paediatric wards in European countriesBMJ, 2000
- Adverse drug reactions to unlicensed and off‐label drugs on paediatric wards: a prospective studyActa Paediatrica, 1999
- Unlicensed and off label drug use in neonates CommentaryArchives of Disease in Childhood - Fetal and Neonatal Edition, 1999
- Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective studyActa Paediatrica, 1999